{"id":"medi3506","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Rash"},{"rate":"5-15%","effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"MEDI3506 works by binding to PD-L1, preventing its interaction with PD-1 and thereby enhancing T-cell mediated anti-tumor immune response.","oneSentence":"MEDI3506 is a monoclonal antibody targeting PD-L1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:59:52.275Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT06040086","phase":"PHASE3","title":"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-22","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1454},{"nctId":"NCT05742802","phase":"PHASE3","title":"Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-06","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1713},{"nctId":"NCT06897748","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":98},{"nctId":"NCT06908577","phase":"PHASE1","title":"An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-04-07","conditions":"Healthy Participants","enrollment":254},{"nctId":"NCT05624450","phase":"PHASE3","title":"Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-13","conditions":"Viral Lung Infection and Acute Respiratory Failure","enrollment":2870},{"nctId":"NCT04631016","phase":"PHASE2","title":"A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-14","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis","enrollment":137},{"nctId":"NCT04170543","phase":"PHASE2","title":"A Phase 2b Diabetic Kidney Disease Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-11-18","conditions":"Diabetic Kidney Disease","enrollment":609},{"nctId":"NCT04570657","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-09-17","conditions":"Asthma","enrollment":250},{"nctId":"NCT04212169","phase":"PHASE2","title":"Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-12-09","conditions":"Atopic Dermatitis","enrollment":148},{"nctId":"NCT05070312","phase":"PHASE1","title":"Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-08-23","conditions":"Healthy Volunteer","enrollment":39},{"nctId":"NCT03096795","phase":"PHASE1","title":"Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2017-05-15","conditions":"Part I (SAD) - Healthy Participants, Part II (MAD) - Chronic Obstructive Pulmonary Disease, Part III (J-SD) - Healthy Japanese Participants","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"MEDI3506","genericName":"MEDI3506","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Biologic","firstApprovalDate":"","aiSummary":"MEDI3506 is a monoclonal antibody targeting PD-L1. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}